Lund, SE — October 3, 2025 — Leads & Copy — BioInvent International AB (“BioInvent”) (STO:BINV)(Nasdaq Stockholm:BINV) will present a poster with data from its trial of BI-1910 at the upcoming Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting to be held November 5-9, 2025, at National Harbor, MD (USA). The abstract title, which was released today, is “Preliminary Phase 1 results of clinical trial investigating BI-1910, a Tumor Necrosis Factor Receptor 2 (TNFR2) agonist in solid cancer tumor patients.”
BI-1910 is part of BioInvent’s tumor-associated regulatory T cells (Treg)-targeting program. Following a comprehensive strategic review – BioInvent decided to concentrate on advancing BI-1808 (as well as BI-1206, an FcyRIIB-blocking antibody) and is pausing the development of BI-1910, according to an announcement made in August of this year.
TNFR2 is particularly upregulated on Tregs of the tumor microenvironment and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy.
Poster details:Title: Preliminary Phase 1 results of clinical trial investigating BI-1910, a Tumor Necrosis Factor Receptor 2 (TNFR2) agonist in solid cancer tumor patients.Abstract number: 581Date: November 7-8, 2025Authors: Hernandez T., Doger B., Yachnin J., Staahl Rorberg K., Moreno I., Carneiro A., Falcon Gonzalez A., Holmkvist P., Karlsson I., Lindahl D., Meller M., Mårtensson L., Schoenborn-Kellenberger O., Sundstedt A., Teige I., Piliuhin D., Vaapil M., Wallin J., Frendéus B., McAllister A.
The abstract will be published in the Journal for ImmunoTherapy of Cancer ( JITC ) Abstract Supplement. A link to the supplement will be posted on the SITC website on November 4, 2025.
During this part of the Phase 1/2a study the safety, tolerability, and potential signs of efficacy of BI-1910 as a single agent were evaluated in patients with advanced solid tumors.The single agent dose escalation of BI-1910 in the Phase 1 study has successfully been completed without any notable adverse events. Out of the 12 evaluable patients, six patients displayed stable disease. Early results indicated favorable pharmacokinetic data and robust target engagement, with patients in the target dose range showing evidence of induction of T cell proliferation.
BI-1910 offers a differentiated, agonist approach to cancer treatment compared to BI-1808, BioInvent’s first-in-class anti-TNFR2 antibody currently in a Phase 1/2a development. Both monoclonal antibodies were chosen as potential best-in-class, from a large family of binders generated through BioInvent’s proprietary F.I.R.S.T ™ technology platform.
BI-1910 is an agonistic human IgG2 mAb targeting TNFR2. BI-1910 stimulates T cells and enhances the activation of both CD4+ and CD8+ T cells. It binds selectively to TNFR2 without inhibiting TNF-a binding. In preclinical models, BI-1910 combined with anti-PD1 showed additive anti-tumor activity, justifying clinical evaluation with pembrolizumab.
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
Source: BioInvent International AB
